Aligos Therapeutics (NASDAQ:ALGS) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Aligos Therapeutics (NASDAQ:ALGS) from a sell rating to a strong sell rating in a research report sent to investors on Saturday.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Westpark Capital started coverage on Aligos Therapeutics in a report on Thursday, March 26th. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Trading Up 6.8%

NASDAQ ALGS opened at $6.44 on Friday. The business’s 50 day moving average is $7.10 and its two-hundred day moving average is $8.16. Aligos Therapeutics has a 12-month low of $4.47 and a 12-month high of $13.69. The stock has a market capitalization of $39.86 million, a price-to-earnings ratio of -0.74 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 119.24% and a negative net margin of 1,919.68%.The company had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million. Equities analysts forecast that Aligos Therapeutics will post -7.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after acquiring an additional 5,978 shares during the period. Rockefeller Capital Management L.P. lifted its stake in Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC purchased a new stake in Aligos Therapeutics in the 3rd quarter valued at approximately $98,000. Susquehanna International Group LLP purchased a new stake in Aligos Therapeutics in the 3rd quarter valued at approximately $99,000. Finally, LPL Financial LLC lifted its stake in Aligos Therapeutics by 19.7% in the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after buying an additional 10,880 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.